IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
IDEAYA Biosciences (NASDAQ: IDYA) announced participation in two virtual investor events in February 2026: Citi's Virtual Oncology Leadership Summit on February 18, 2026 at 1:00 PM ET, and IDEAYA's virtual fireside hosted by Evercore on February 23, 2026 at 12:00 PM ET.
Senior executives including the CEO, CMO, CSO, and CFO will appear. Live audio webcasts will be available via the company "Investors/Events" page, with replays accessible for 30 days after each event.
Details
News Market Reaction – IDYA
On Feb 2, the day this news came out, IDYA closed 5.81% above the previous close.
Data tracked by StockTitan Argus for the Feb 2 session.
Key Figures
- Citi summit date
- February 18, 2026, 1:00 PM ET
- Citi 2026 Virtual Oncology Leadership Summit fireside chat
- Evercore ISI chat date
- February 23, 2026, 12:00 PM ET
- IDEAYA virtual fireside chat hosted by Evercore ISI
- Webcast replay period
- 30 days
- Replay of investor event webcasts available after live events
- 52-week range
- $13.45 – $39.28
- Pre-news 52-week low and high for IDYA
- Market cap
- $2,892,114,800
- Pre-news market capitalization for IDYA
- Price vs 52-week low
- 139.33% above
- Pre-news level relative to 52-week low of $13.45
Historical Context
-
J.P. Morgan Healthcare Conference presentation and webcast details.
-
Completion of full enrollment in pivotal OptimUM-02 darovasertib trial.
-
IND submission for IDE574, a KAT6/7 dual inhibitor, to the FDA.
-
FDA IND clearance for IDE034 ADC licensed from Biocytogen.
-
FDA IND clearance for IDE034, enabling a Phase 1 solid tumor trial.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Citi's 2026 Virtual Oncology Leadership Summit
Wednesday, February 18th, 2026 at 1:00 PM ET
- Fireside chat with Darrin Beaupre, Chief Medical Officer; Michael White, Chief Scientific Officer; and Joshua Bleharski, Chief Financial Officer, hosted by Yigal D. Nochomovitz, Ph.D., Director, SMid Cap Biotech Analyst
IDEAYA Biosciences' Virtual Fireside Chat hosted by Umer Raffat of Evercore ISI
Monday, February 23rd, 2026 at 12:00 PM ET
- Fireside chat with Yujiro S. Hata, President and Chief Executive Officer; Darrin Beaupre, Chief Medical Officer; Michael White, Chief Scientific Officer; and Joshua Bleharski, Chief Financial Officer, hosted by Umer Raffat, Senior Managing Director, Biotech and Pharma Equity Research.
A live audio webcast of the events will be available under the "Investors/Events" section of the IDEAYA website at https://ir.ideayabio.com/events and/or through the conference host. A replay of the webcasts will be accessible for 30 days following the live events.
About IDEAYA Biosciences
IDEAYA is a precision medicine oncology company committed to the discovery, development, and commercialization of transformative therapies for cancer. Our approach integrates expertise in small-molecule drug discovery, structural biology and bioinformatics with robust internal capabilities in identifying and validating translational biomarkers to develop tailored, potentially first-in-class targeted therapies aligned to the genetic drivers of disease. We have built a deep pipeline of product candidates focused on synthetic lethality and antibody-drug conjugates, or ADCs, for molecularly defined solid tumor indications. Our mission is to bring forth the next wave of precision oncology therapies that are more selective, more effective, and deeply personalized with the goal of altering the course of disease and improving clinical outcomes for patients with cancer.
Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's current and future filings with the
Investor and Media Contact
IDEAYA Biosciences
Joshua Bleharski, Ph.D.
Chief Financial Officer
investor@ideayabio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ideaya-biosciences-to-participate-in-upcoming-february-2026-investor-relations-events-302675666.html
SOURCE IDEAYA Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.